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ILLUSTRATIVE CASE
Your new patient is a 57-year-old African 
American man. His blood pressure is 150/95 
mm Hg, fasting glucose 115 mg/dL, body 
mass index 32, and triglycerides 155 mg/dL; 
he is on no prior medications. During the 
course of his care you diagnose hyperten-
sion with metabolic syndrome and decide to 
recommend an antihypertensive. Thiazide-
type diuretics are your standard initial thera-
py, but this patient has metabolic syndrome, 
and you know that certain antihypertensive 
agents have a more favorable metabolic 
profi le than thiazide diuretics. Furthermore, 
metabolic differences among races have 
been touted as reason to use other agents 
in black patients. Should you recommend a 
thiazide diuretic, or another agent? 
Until now, we’ve had no simple ap-proach to treating hypertension in patients with metabolic syn-
drome—and half or more of our hyper-
tensive patients over the age of 55 have 
this disorder. 
Now, however, we can base decisions 
on clinical outcomes data from a subgroup 
analysis of the Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart At-
tack Trial (ALLHAT).1 This new subgroup 
analysis supports use of thiazide-type di-
uretics in these patients—particularly in 
black patients—despite the more favor-
able metabolic profi le of calcium channel 
blockers, alpha-blockers, and angiotensin-
converting enzyme (ACE) inhibitors.
Cost is no longer as big a factor as it 
once was, now that ACE inhibitors and 
alpha-blockers, as well as thiazide diuret-
ics, are available generically.
❚  Does a better metabolic 
proﬁ le improve outcomes? 
We have had reason to be concerned 
about the metabolic adverse effects of 
thiazide-type diuretics in the past. Studies 
published before this ALLHAT subgroup 
analysis showed that hydrochlorothiazide 
for essential hypertension had adverse 
effects on potassium, glucose, and lipid 
metabolism. Some speculated that these 
changes aggravate the metabolic changes 
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in early diabetes2-4 and may contribute to 
increased coronary heart disease risk.5,6
ACE inhibitors and ARBs 
The metabolic benefi ts of ACE inhibitors 
and angiotensin-receptor blockers (ARBs) 
are widely known. In comparative stud-
ies prior to this ALLHAT subgroup anal-
ysis, ACE inhibitors were thought to be 
preferable to thiazide diuretics and beta-
blockers for patients with obesity7 or the 
metabolic syndrome.8 These agents also 
protect against diabetic nephropathy.9
Other studies attribute additional vascu-
lar benefi ts to ACE inhibitors,10 beyond 
that of lowering blood pressure.
A 2005 meta-analysis by Abuissa 
et al11 showed that ACE inhibitors and 
ARBs were associated with signifi cant 
reductions in the incidence of newly di-
agnosed diabetes, which, in turn, might 
lead to reduced heart disease. That report 
concluded that use of ACE inhibitors or 
ARBs should be considered in patients 
with prediabetic conditions such as meta-
bolic syndrome, hypertension, impaired 
fasting glucose, family history of diabetes, 
obesity, congestive heart failure, or coro-
nary heart disease.
Calcium-channel blockers 
and alpha-blockers
Calcium-channel blockers and alpha-
blockers also do not appear to have the 
adverse metabolic effects of thiazides, 
and have also been advocated over beta-
blockers and thiazides for hypertensive 
patients with metabolic syndrome.12-15
Racial differences
In a consensus statement developed be-
fore the fi ndings from the ALLHAT 
subgroup analysis were available, it was 
noted that racial differences in metabolic 
syndrome may make the selection of an-
tihypertensive agents particularly impor-
tant in African American patients.16
❚ ALLHAT and JNC7 
recommendations
The 2002 ALLHAT demonstrated that 
chlorthalidone (a thiazide-type diuretic) 
is superior to lisinopril, amlodipine, and 
ACE inhibitors, 
ARBs, calcium-
channel blockers, 
and alpha-blockers 
have better 
metabolic proﬁ les 
than thiazides
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Outcomes favor thiazides
We know many physicians who have adopted
thiazide-type diuretics as the fi rst-line treatment for
hypertension in metabolic syndrome, but until now, 
data have been inadequate to support this decision. 
A subgroup analysis from the ALLHAT1 concludes: 
“The ALLHAT fi ndings fail to support the 
preference for calcium channel blockers, alpha-
blockers, or angiotensin-converting enzyme 
inhibitors compared with thiazide-type diuretics 
in patients with the metabolic syndrome, despite
their more favorable metabolic profi les. This 
was particularly true for black participants.”
Hypertension
Blood pressure target for 
patients enrolled in the ALLHAT 
was <140/90 mm Hg 
Metabolic syndrome, in the subgroup analysis, was defi ned as hypertension 
plus 2 of the following risk factors for coronary heart disease:
1. Obesity
Body mass index at least 30
2. Lipid disorder
Fasting triglyceride level 
>150 mg/dL and high-den-
sity lipoprotein cholesterol 
level <40 mg/dL in men, or 
<50 mg/dL in women
3. Glycemic disorder
Fasting glucose level 
>100 mg/dL, or nonfasting 
glucose level >200 mg/dL, 
or history of diabetes
FIGURE
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doxazosin in preventing 1 or more ma-
jor forms of cardiovascular disease. No 
difference was observed, however, for 
fatal coronary heart disease, nonfatal 
myocardial infarction, or all-cause mor-
tality.17 These fi ndings persisted in sub-
group analyses stratifi ed by race, diabet-
ic status, and level of renal function, but 
ALLHAT did not identify patients with 
metabolic syndrome a priori. 
The ALLHAT infl uenced the 2003 
Joint National Commission VII (JNC7) 
Report, which recommends thiazide 
diuretics for fi rst-line treatment of hy-
pertension in the absence of compelling 
indications to begin an alternative anti-
hypertensive agent.18 
Special consideration, but no recom-
mendation. The JNC7 Report mentions 
the metabolic syndrome as a special con-
sideration, but does not explicitly rec-
ommend a fi rst-line therapy other than 
thiazides. 
Anecdotally, we know many physi-
cians who have adopted thiazide-type 
diuretics as the fi rst-line treatment for 
hypertension in metabolic syndrome, but 
until now, data have been inadequate to 
support this decision. 
STUDY SUMMARY
❚  Chlorthalidone outcomes 
were equivalent or better
Wright and colleagues analyzed a sub-
group1 of the ALLHAT cohort, which 
consisted of 42,418 participants, aged 
≥55, with hypertension and at least 1 
other cardiovascular risk factor (FIGURE). 
Patients were randomly assigned to ther-
apy with chlorthalidone, amlodipine, 
lisinopril, or doxazosin. After random-
ization, if patients failed to reach the 
target blood pressure (<140/90 mm Hg) 
with their assigned therapy, they were 
started on atenolol, clonidine, or reser-
pine. If they required a third agent, they 
received hydralazine. The doxazosin 
arm was stopped early due to increased 
stroke and heart failure risk.
The ALLHAT was well done and 
designed for adequate power to evaluate 
clinical outcomes in racial subgroups, as 
well as the general population. 
Outcomes were compared by race in 
hypertensive patients with and without 
metabolic syndrome. 
A total of 23,077 (54%) patients met 
all criteria; 12,818 were black, 7327 (57%) 
of whom had metabolic syndrome.
Not surprisingly in a study of this 
size, the expected metabolic effects of all 
4 antihypertensive agents were detected. 
Patients taking chlorthalidone had high-
er glucose levels (1–4 mg/dL) and higher 
levels of cholesterol, although these high-
er glucose and cholesterol levels were not 
statistically signifi cant for all comparisons 
over time and between different drugs.
Outcomes in the chlorthalidone 
group were equivalent or superior to the 
3 other therapies, generally. This pattern 
held true regardless of race (TABLE): 
Heart failure rates were signifi cantly high-
er in patients with metabolic syndrome 
across all treatments compared with 
chlorthalidone. 
Combined cardiovascular disease rates 
were higher with lisinopril and doxazo-
sin compared with chlorthalidone. 
Stroke rates were higher among black par-
ticipants only in the lisinopril group. 
I t is unclear to us how this confl icting information has played out in current practice. We know that many physicians al-
ready choose thiazides as their fi rst-line agent for hypertensive 
patients with metabolic syndrome. And we suspect that many 
choose other agents. 
 We analyzed the National Ambulatory Medical Care Survey 
data (http://www.cdc.gov/nchs/about/major/ahcd/ahcd1.htm) 
from 2004 and 2005 and found that only 3% to 5% of outpa-
tients with diabetes and hypertension were taking thiazides at 
all (unpublished data). Metabolic syndrome is not a variable in 
this dataset, so we could not determine the use of thiazides in 
hypertension and metabolic syndrome.
 Our informal polling of colleagues suggested that large 
numbers of hypertensive patients with metabolic syndrome 
are not currently receiving the more benefi cial thiazides.
How is conflicting information 
playing out in practice?
Some physicians 
already use 
thiazides for 
hypertension 
with metabolic 
syndrome
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WHAT’S NEW
❚  Most effective,
least expensive
First-line use of thiazide diuretics for hy-
pertension gained major support from 
the fi ndings of the fi rst ALLHAT report, 
published in 2002. A year later, JNC7 
supported the practice. Yet questions 
have persisted about whether the choice 
of initial antihypertensive agent in pa-
tients with metabolic syndrome warrants 
special consideration.
The difference for one patient is 
small, but when you consider the high 
prevalence of  hypertension, the cumu-
lative benefi t at a population level is sig-
nifi cant. This subgroup analysis confi rms 
that there is no harm, and potentially 
a small benefi t, in using chlorthalidone 
as a fi rst-line agent for treating hyper-
tension in patients with metabolic syn-
drome, regardless of race—despite the 
measurable and presumably adverse 
effects of diuretic agents on metabolic 
measurements. 
How large is the beneﬁ t 
of ﬁ rst-line thiazides, overall?
Although, statistically, the relative risks 
(RR) are not large, the sheer number of 
patients means that there is signifi cant 
benefi t to the selection of thiazides as 
fi rst-line treatment in most patients. 
CAVEATS
❚  Is stroke a concern?
Was follow-up sufﬁ cient?
In this study, the only fi nding of harm in 
the diuretic group was an increased risk 
for stroke compared with amlodipine 
among non-black patients with meta-
bolic syndrome. While this fi nding does 
raise some uncertainty, we still think that, 
on balance, thiazides are the most benefi -
cial, even in this subgroup, as there was a 
larger benefi t in preventing heart failure.
Another theoretical possibility is that 
follow-up was too short to demonstrate 
harm from the metabolic effects of thia-
zides. However, the metabolic effects of 
thiazides are very small and we believe 
that the evidence of benefi t shown during 
this study period easily outweighs any 
such theoretical harms.
We also assume that hydrochlorothi-
azide, a commonly prescribed thiazide, 
has the same benefi ts as chlorthalidone, 
the medication studied.
Most ALLHAT participants with 
metabolic syndrome already had diabetes: 
67.6% of black participants and 51.8% 
of non-black participants. Another sub-
group analysis of the ALLHAT studied 
patients with metabolic syndrome with-
out diabetes, and found similar results.19 
Of note, lisinopril reduced the onset of 
diabetes over 5 years (number needed 
Number needed to treat to prevent blood pressure-related adverse outcomes 
in patients with hypertension and metabolic syndrome
NUMBER NEEDED TO TREAT (NNT)  = number of patients that would need to take chlorthalidone to prevent 1 outcome, 
compared with the alternate drug (4.9 years of chlorthalidone instead of lisinopril or amlodipine or 3.2 years of chlorthalidone 
instead of doxazosin). Smaller numbers indicate a bigger effect.
OUTCOME
CHLORTHALIDONE
VS AMLODIPINE
CHLORTHALIDONE
VS LISINOPRIL
CHLORTHALIDONE
VS DOXAZOSIN
Black Non-black Black Non-black Black Non-black
Combined cardiovascular disease 22 NS 18 53 14 34
Stroke NS -111 59 NS 37 NS
Heart failure 29 48 28 143 28 25
All-cause mortality NS NS NS NS NS NS
NS = not signifi cant.
Source: The authors calculated the NNTs from the event rates reported.1
TABLE
There is no harm 
and potentially a 
small beneﬁ t 
despite presumably
adverse effects 
of diuretics on 
metabolic 
measurements
C O N T I N U E D
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to treat [NNT] = 22.2), at the cost of in-
creased heart failure (RR = 1.31; 95% 
confi dence interval [CI], 1.04-1.64) and 
combined cardiovascular disease (RR = 
1.19; 95% CI, 1.07-1.32). This potential-
ly confounds the claim that thiazides are 
effective in preventing diabetes, since so 
many people had it to begin with.
The criteria for metabolic syndrome 
did not include waist circumference, which 
is the National Cholesterol Education Pro-
gram defi nition. The World Health Orga-
nization defi nition, however, does allow 
substitution of BMI. Purists would have 
you believe waist circumference is neces-
sary. In practice, we have come to use BMI 
as an adequate surrogate. Some say it has, 
in fact, replaced waist circumference.
CHALLENGES TO IMPLEMENTATION
❚  Inertia
Few interventions are as simple as this. 
Thiazide diuretics are well tolerated, need 
to be taken only once daily, and are in-
expensive. Because generics are available, 
little to no pharmaceutical marketing is 
done to promote their use. The major bar-
riers to implementing this practice may be 
overcoming clinical inertia, and the mes-
sage of pharmaceutical marketing on be-
half of the more expensive alternatives. ■
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